&nbsp;

Sep 2025

Drug

anastrozole

Other Name(s): Arimidex®

Quick Link(s):

Updated

Dec 2025

Drug

niLOtinib

Other Name(s): Tasigna®

Quick Link(s):

Jul 2025

Drug

arsenic trioxide

Other Name(s): Trisenox®

Quick Link(s):

Oct 2025

Drug

nivolumab

Other Name(s): Opdivo®

Quick Link(s):

Dec 2025

Drug

alectinib

Other Name(s): Alecensaro®

Quick Link(s):

Nov 2025

Drug

atezolizumab

Other Name(s): Tecentriq™

Quick Link(s):

Jul 2025

Regimen

NILO

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

niLOtinib - Chronic phase Ph+ CML, with specific criteria

Exceptional Access Program

niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria

Drugs Used:

niLOtinib

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

NPAC(W)

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

New Drug Funding Program

Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Jul 2025

Regimen

ALEC

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

alectinib - Treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer, according to specific criteria

Drugs Used:

alectinib

Quick Link(s):

Regimen Monograph

Dec 2025

Regimen

AVEL

Cancer Type:

Skin,

Merkel Cell

Intent: Palliative

Funding:

New Drug Funding Program

Avelumab - Metastatic Merkel Cell Carcinoma

Drugs Used:

avelumab